Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Argireline6 residues (approx.)EEMQRREach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8, AH-8
One clinical trial measured 48.9% wrinkle reduction in four weeks. Another found zero statistically significant change. That split tells you everything about Argireline (Acetyl Hexapeptide-8, CAS 616204-22-9), a six-amino-acid topical peptide that competes with SNAP-25 to slow acetylcholine release at the neuromuscular junction. The mechanism mirrors botulinum toxin, but less than 0.01% of the applied peptide actually reaches the epidermis. Skincare enthusiasts use it twice daily at 10% concentration to soften forehead lines and crow's feet. It works for some people. For others, the serum vehicle does all the heavy lifting.
Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3, CAS 616204-22-9) is a synthetic hexapeptide with the sequence Ac-EEMQRR-NH2 and a molecular weight of 889 Da. Clinical results are polarizing: 48.9% composite wrinkle reduction in one trial, zero significant effect in another, both using the same concentration. Developed by Lipotec (now Lubrizol), it was designed to mimic residues 12 through 17 of the SNAP-25 N-terminal domain. That stretch of amino acids participates in assembling the SNARE complex, the molecular machinery behind acetylcholine release at neuromuscular junctions. By competing with SNAP-25 for its binding position, Argireline reduces the efficiency of vesicle fusion. Muscle contractions weaken. Dynamic wrinkles soften. Unlike botulinum toxin type A, which proteolytically cleaves SNAP-25, the inhibition is reversible and dose-dependent. The catch is penetration. In vitro data from Kraeling and colleagues [1] shows 0.22% retention in the stratum corneum. Roughly 0.01% reaches the epidermis. Nothing detectable arrives in the dermis. The neuromuscular mechanism that makes Argireline interesting on paper may not operate at topical doses. Clinical evidence is mixed. Wang and colleagues [2] ran a placebo-controlled trial with 60 subjects and reported statistically significant roughness reduction (p < 0.01) at four weeks. A 2023 double-blind split-face study with 19 subjects (PMC10665711) found no significant between-group difference. Community evidence is large; The Ordinary's 10% solution has 200,000 plus reviews (3.9 out of 5 stars). Responders are vocal. Non-responders are equally vocal. Argireline is classified as a cosmeceutical ingredient. It has no FDA approval for any medical indication. The CIR Expert Panel confirmed its safety in cosmetic formulations.
The SNARE complex is a three-protein machine. Syntaxin-1 and SNAP-25 sit on the presynaptic membrane. VAMP (synaptobrevin-2) anchors to the synaptic vesicle. When these three proteins zip together, they generate enough force to fuse the vesicle with the membrane and dump acetylcholine into the synaptic cleft. That acetylcholine triggers muscle contraction. Argireline's six-amino-acid sequence (Ac-EEMQRR-NH2) copies residues 12 through 17 of SNAP-25's N-terminal SNARE motif. The peptide inserts itself into the binary interaction between SNAP-25 and syntaxin, the first step of SNARE assembly. With Argireline occupying that binding site, the ternary complex can't form efficiently. Less complex formation means fewer vesicles fuse. Fewer fused vesicles means less acetylcholine in the cleft. Less acetylcholine means weaker contraction of the frontalis, orbicularis oculi, and corrugator supercilii muscles. Those are the muscles that carve forehead furrows, crow's feet, and glabellar frown lines over years of repeated expression. The pharmacological distinction from botulinum toxin is important. Botulinum toxin type A irreversibly cleaves SNAP-25 through proteolysis. The nerve terminal has to grow new SNAP-25 before function returns. Argireline is a competitive inhibitor; it modulates contraction rather than eliminating it. Stop applying it, and normal SNARE assembly resumes within weeks. One unresolved question hangs over the entire mechanism. In vitro penetration studies show less than 0.01% of applied Argireline reaching the epidermis. Whether enough peptide reaches neuromuscular junctions to produce the measured wrinkle reduction (or whether the effect is partly vehicle-driven) is something the published literature has not settled.
Modest, inconsistent efficacy for expression line reduction at 10% concentration. Two positive RCTs (n=60 and open-label n=10) support benefit; one 2023 double-blind n=19 RCT found no statistically significant effect. Primary limitation is penetration: <0.01% of applied peptide reaches the epidermis, raising mechanistic questions about neuromuscular access.
Wang et al. 2013 (PMID 23417317): RCT n=60, 48.9% composite anti-wrinkle efficacy at 4 weeks (p<0.01); counterbalanced by PMC10665711 (2023) n=19 double-blind split-face: p=0.060 treated side, p=0.829 between-group: no significant effect.
Small sample sizes; industry-adjacent funding in positive trials; no confirmed neuromuscular mechanism in vivo at topical doses; penetration barrier (<0.01% epidermis); no placebo-matched studies exceeding 60 subjects.
Broadly popular for softening forehead furrows and crow's feet. Results are polarized: enthusiastic responders report visible improvement; a meaningful minority sees no effect. The "Botox in a bottle" label drives adoption but also disappointment when results don't match Botox.
Both science and community accept Argireline can reduce surface wrinkle appearance, but the community believes more strongly than the evidence supports. Science is split on whether the effect is real vs. vehicle-driven. The penetration data creates a mechanistic gap that neither fully resolves.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | 2x Daily |
| Moderate | 5mg | 2x Daily |
| Aggressive | 10mg | 2x Daily |
Start with a 5% concentration for the first two weeks if your skin runs reactive. One study landed on nearly identical wrinkle reduction at 5% vs. 10% (16.26% vs. 17%), so you're not losing much during the tolerance phase. After that, step up to 10% twice daily. Argireline is a topical peptide, not an injectable. There's no vial to reconstitute, no bacteriostatic water, no syringe math. You're buying a ready-to-use serum or cream. The Ordinary's 10% solution at $10 for 30ml is the community benchmark; use it to calibrate your expectations before spending more on premium formulations. The thing most beginners miss: check the label carefully. Some products list "contains Argireline" when the peptide is a trace ingredient in a blend. You want 10% Acetyl Hexapeptide-8 as the active, listed early in the INCI order. Apply to clean, dry skin before moisturizer. Morning and evening. Give it 2 to 3 minutes to absorb before layering. Refrigerate opened bottles and use within six months.
Apply twice daily for 12 weeks to allow cumulative wrinkle reduction. Clinical improvement typically begins around week 2-3 and peaks at week 4-8. A 2-week break is optional: no receptor desensitization or tachyphylaxis has been reported, so continuous long-term use is commonly practiced. Effects are reversible and diminish gradually over 4-8 weeks after discontinuation as normal SNARE complex function resumes.
Argireline has no documented receptor desensitization, tachyphylaxis, hormonal axis effects, or antibody formation. Cycling is not pharmacologically required. The standard 12-week-on / 2-week-off practice used in the peptides.ts entry is derived from cosmetic study durations (most trials lasted 4–12 weeks) and provides a natural reassessment window rather than a biological necessity. Continuous long-term use is widely practiced and no adverse effects from sustained use have been documented in the CIR safety assessment or clinical literature.
Or use the universal Peptide Calculator for any peptide.
Expected: Modest softening of fine expression lines by week 4; non-responders apparent by week 8
Monitor: Self-assessment of expression line depth at 4 and 8 weeks. Discontinue if contact dermatitis develops.
Argireline absorbs best on clean, dry skin without competing products underneath.
Dispense 3 to 4 drops of 10% Argireline serum onto your fingertips.
Apply a thin layer to target expression-line areas: forehead horizontals, crow's feet, glabellar frown lines, and periorbital region. Use gentle tapping motions rather than rubbing.
Wait 2 to 3 minutes for absorption before applying your next product.
In the morning, follow with sunscreen (SPF 30 or higher).
Repeat morning and evening for at least four weeks before evaluating results.
Timing with retinol: apply Argireline in the morning, retinol in the evening. Don't layer them simultaneously.
After chemical exfoliation at peel-strength concentrations (glycolic above 20%), wait 48 to 72 hours before resuming Argireline.
Do not apply to broken, inflamed, or sunburned skin.
Store opened serum at 2 to 8 degrees Celsius away from direct light. Room temperature is acceptable for sealed commercial products with preservative systems.
Note: Argireline is a topical peptide, not an injectable. There are no syringe unit calculations for this product. The dosing tiers (2 mg beginner, 5 mg moderate, 10 mg aggressive twice daily) reflect approximate milligrams of active peptide per application when using commercial serums at standard concentrations.
N/A: this is the reference route
All published RCTs used topical emulsion or serum. In vitro penetration: 0.22% retained in stratum corneum, <0.01% reaches epidermis, nothing detectable in dermis (PMID 24754410).
Same 5–10% active concentration but potentially higher dermal bioavailability due to lipid carrier bypassing the hydrophilic barrier limitation
Multiple-water-in-oil-in-water (w/o/w) emulsions and phosphatidylcholine liposomes show improved AH-8 retention in deeper skin layers in ex vivo models (referenced in PMC12193160). No commercial benchmark at this formulation type yet. DIY liposomal encapsulation is technically complex.
Lower % concentration may be required as delivery efficiency is dramatically higher; exact equivalent dose not established
Dissolving microneedle patches with AH-8 have been studied in vitro showing meaningful dermal deposition. No commercial microneedle patch product for Argireline is widely available as of 2026. Most accessible approach is using a 0.25–0.5mm dermaroller prior to standard topical application (community practice; no RCT data).
Same SNARE complex inhibition mechanism, longer octapeptide sequence. Additive neuromuscular effect at the same target site. Frequently combined in multi-peptide anti-wrinkle serums.
Argireline 10% AM + SNAP-8 10% PM; or combined in same serum formulation
Collagen-stimulating mechanism (TGF-β pathway) complements surface wrinkle relaxation. Addresses structural collagen loss while Argireline targets neuromuscular dynamic wrinkles.
Combined in same serum or layered AM routine; both 2x daily
Collagen/elastin remodeling and wound-healing support at a different mechanistic layer. GHK-Cu works deeper on ECM structure; Argireline on surface neuromuscular relaxation. Frequently combined in anti-aging protocols.
Argireline AM; GHK-Cu PM or combined in the same multi-peptide serum
Waglerin-1-mimetic peptide that blocks postsynaptic nicotinic acetylcholine receptors: a third, complementary neuromuscular relaxation pathway distinct from Argireline's presynaptic SNARE inhibition.
Combined in premium multi-peptide serums; each at 4–8% concentration
Compromised barrier post-peel alters peptide absorption unpredictably. May cause excessive irritation or sensitization.
Do not apply topicals to injection sites immediately after Botox. Theoretical additive muscle relaxation effect in the treatment zone; skin trauma from injection alters topical absorption.
Pricing updated 2026-04-09
The biggest concern with Argireline is not a side effect. It's the anecdotal reports of periorbital heaviness and a "sagging" sensation around the eyes with heavy use. No published trial has documented this, but it recurs across Reddit threads with enough consistency to warrant attention. If you notice your eyelids feeling heavier after several weeks of use, reduce application frequency around the eyes to once daily (evening only) or stop using it in the periorbital area altogether. From a clinical standpoint, the side effect profile is genuinely mild. Published studies report no significant adverse events compared to vehicle control. Kraeling and colleagues [1] showed less than 0.3% of applied peptide penetrates beyond the skin surface, so systemic effects are not a realistic concern. Skin irritation at the application site can occur. Mild redness or a tingling sensation after application is the most commonly reported reaction, particularly in people with reactive or sensitized skin. In the blepharospasm pilot study [4], minor eyelid irritation was attributed to the cream vehicle rather than Acetyl Hexapeptide-8 itself. Allergic contact dermatitis is possible but rare. If you develop persistent redness or itching, stop for one week. If symptoms resolve, reintroduce every other day. If they persist, patch-test the individual ingredients because the reaction may be to phenoxyethanol or propanediol in the serum base. No oral toxicity or primary irritation was observed at high doses in preclinical safety testing. The CIR Expert Panel reviewed the safety data and confirmed the ingredient is safe for cosmetic use. A few practical cautions apply. Don't apply Argireline immediately after a strong chemical peel (glycolic acid above 20%, TCA peels); a compromised barrier changes absorption unpredictably. Wait 48 to 72 hours post-peel before resuming. If you're also receiving botulinum toxin injections, avoid applying topicals to the injection sites for at least 24 to 48 hours. Pregnancy and breastfeeding: no safety data exists for these populations. Standard practice is to avoid use. The same applies to children under 18.
Verify Argireline dosing and safety with a second opinion
Sold as a standard OTC cosmeceutical ingredient regulated under cosmetics law (FDA 21 CFR, EU Cosmetics Regulation). Commercial products from reputable brands (The Ordinary/DECIEM, Timeless) undergo standard cosmetic GMP manufacturing and preservative efficacy testing. The raw ingredient (AH-8) is a well-characterized synthetic hexapeptide from established cosmetic ingredient suppliers (Lipotec/Lubrizol). Primary quality variable for consumers is actual % concentration: some products list Argireline as a minor ingredient in a "peptide blend" rather than at the labeled 10%.
| Test | When | Target |
|---|---|---|
| Baseline + 4-week photography (expression lines) | Week 0 and Week 4 | Visible reduction in expression line depth or roughness in consistent lighting conditions |
| Skin tolerance self-assessment | Days 3, 7, and 14 of initial use | — |
Objective before/after comparison to detect responder vs. non-responder status early; expression wrinkles are highly subject to lighting and facial position bias without photographic standardization
Contact dermatitis or irritant reaction identification; most reactions present within the first 2 weeks. Allows switching to every-other-day protocol or vehicle-only control if irritation occurs
No visible changes expected. Argireline begins accumulating in the upper skin layers upon twice-daily application. Some users notice a mild smoothing or tightening sensation immediately after application due to the serum vehicle. Skin tolerance is established during this period.
Early wrinkle softening becomes apparent, especially on fine expression lines. The original Blanes-Mira study reported up to 30% wrinkle depth reduction by day 30. Surface roughness parameters begin to decrease measurably. Fine lines around the eyes and forehead show the most noticeable initial improvement.
Peak anti-wrinkle effects are typically reached in this window. The randomized Chinese clinical trial reported 48.9% total efficacy at 4 weeks with statistically significant roughness reduction (p < 0.01). Results vary based on concentration (10% formulations outperform lower concentrations), formulation quality, and individual skin penetration characteristics.
Maintenance of wrinkle reduction gains with continued twice-daily use. Deeper expression lines may show further gradual improvement. Best results are achieved with consistent high-concentration (10%) application combined with complementary peptides such as SNAP-8 or Matrixyl.
Effects are not permanent. Wrinkle depth gradually returns to baseline over 4-8 weeks after discontinuation as normal SNARE complex assembly and muscle contraction patterns resume. Restarting the protocol restores benefits. No rebound worsening has been reported.
Week 1: Don't expect visible changes yet. The peptide accumulates in the upper skin layers with twice-daily application. Some users notice a mild smoothing sensation immediately after applying the serum, but that's the hyaluronic acid vehicle, not the Argireline. This first week is about establishing skin tolerance. Weeks 2 through 4: Fine expression lines start looking softer, particularly around the eyes and forehead. Blanes-Mira's original study [3] measured up to 30% wrinkle depth reduction by day 30 in responders. Surface roughness parameters begin to improve. Non-responders still see nothing at this point, and that's a real possibility. Weeks 4 through 8: This is the peak effect window. Wang and colleagues [2] reported 48.9% composite efficacy at four weeks with p < 0.01 across roughness parameters. But the 2023 split-face study (PMC10665711) with 19 subjects found no statistically significant difference between treated and control sides. If you're a responder, deeper expression lines show clear softening. If you're not, eight weeks is a reasonable cutoff before concluding this peptide doesn't work for your skin. Some users report periorbital heaviness around this stage. Weeks 8 through 12: Gains from the first two months hold steady with continued application. No long-term RCT data exists past four weeks, so this is extrapolation from mechanism. Many community users shift to once-daily maintenance or start incorporating breaks for subjective reassessment. After stopping: Effects are not permanent. Normal SNARE complex assembly and muscle contraction patterns resume within four to eight weeks of discontinuation. Lines reappear gradually. No rebound worsening has been reported. Restarting the protocol restores whatever benefit you had before.
Peptide accumulates in stratum corneum (0.22% retention in in vitro models). No measurable change in wrinkle depth on imaging.
Some users report a mild immediate smoothing or "tightening" sensation: attributable to the serum vehicle (hyaluronic acid base), not the peptide. No visible wrinkle improvement.
Blanes-Mira 2002: up to 30% wrinkle depth reduction measurable by day 30 in responders. Surface roughness parameters begin to decrease.
Enthusiastic responders notice forehead lines and crow's feet looking softer, especially in low-light or morning face conditions. Non-responders see nothing.
Wang 2013: 48.9% composite anti-wrinkle efficacy at 4 weeks in responders (p<0.01). PMC10665711 (2023 RCT): no statistically significant change in n=19 double-blind study. Peak divergence between responder and non-responder groups.
Responders: noticeably smoother expression lines, especially dynamic wrinkles. Non-responders: no visible change by week 6–8: this is the typical cut-off for declaring non-response. Some users anecdotally describe periorbital heaviness at this stage.
No long-term RCT data beyond 4 weeks. Extrapolation from mechanism: continued twice-daily application maintains SNARE inhibition and sustains wrinkle reduction in responders.
Continued improvement plateaus; many users switch to maintenance dosing (once daily) or incorporate periodic breaks for subjective re-assessment.
Reversible mechanism: normal SNARE complex assembly and muscle contraction resume. Wrinkle depth returns to pre-treatment baseline over 4–8 weeks.
Consistent with science: lines reappear over 1–2 months. No rebound worsening reported. Users can resume protocol after break without loss of efficacy.
Source: No systemic pharmacokinetic data available. Argireline is a topical cosmeceutical peptide with negligible transdermal absorption. In vitro skin penetration studies (Kraeling et al. 2015, PMID 24754410) show only 0.22% of applied peptide is retained in the human stratum corneum, ~0.01% reaches the epidermis, and no detectable amounts reach the dermis or systemic circulation. No metabolites (deacetylated H2N-EEMQRR-NH2) were found in any skin layer, indicating the peptide remains intact but does not achieve meaningful systemic exposure.
Loading the interactive decay curve.
Argireline (Acetyl Hexapeptide-8) is classified as a cosmeceutical ingredient. It has no FDA approval for any medical indication and is not regulated as a drug. In the United States, products containing Argireline fall under cosmetics law (FDA 21 CFR) and do not require a prescription. The European Union regulates it under the EU Cosmetics Regulation with no restrictions on concentration. The Cosmetic Ingredient Review Expert Panel has assessed Acetyl Hexapeptide-8 and confirmed its safety in cosmetic formulations. The EWG Skin Deep database rates the ingredient as low risk across all toxicity categories. Argireline is not a WADA-prohibited substance and carries no restrictions for competitive athletes. No pending regulatory changes affect Argireline's availability. It is sold as an over-the-counter cosmetic ingredient through brands including The Ordinary, Timeless, and Depology, and as a raw ingredient through cosmetic suppliers (Making Cosmetics, Lotioncrafter) for DIY formulators. This content is for informational purposes only and does not constitute medical advice. Consult a dermatologist or healthcare provider before starting any new skincare protocol.
Peptide Schedule Research TeamReviewed Apr 202611 Citations
